Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Asciminib, Dasatinib, Prednisone, and Blinatumomab for Participants With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia

NCT06773936 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT06773936
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06773936 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Asciminib, Dasatinib, Prednisone, and Blinatumomab for Participants With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 2
Overall status
Enrolling by invitation
Start date
April 13, 2026
Completion date
July 31, 2033
Enrollment
55 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

cd19+ acute leukemia, philadelphia chromosome positive acute lymphoblastic leukemia